Ahc.Ax

AHC.AX maintains a strong liquidity position, with a current ratio of 1.56 and cash and equivalents amounting to 14.48 million AUD. The company's liquidity is further supported by a low debt-to-equity ratio of 0.14, indicating a conservative capital structure with minimal reliance on long-term debt.

In terms of profitability, AHC.AX reports a return on equity (ROE) of 11.47% and a return on assets (ROA) of 6.52%. These figures suggest that the company is effectively utilizing its equity and assets to generate returns, outperforming the typical expectations for the Medical Equipment, Supplies & Distribution industry.

The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher concentration risk, particularly in the event of a downturn in its primary market.

AHC.AX's growth trajectory appears stable, with a current FY outlook indicating a modest increase in revenue. The company's operating cash flow of 13.42 million AUD and free cash flow of 4.06 million AUD support its ability to fund operations and future growth initiatives.

The risk assessment for AHC.AX indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's capital structure is conservative, and its dilution potential is low, as evidenced by the absence of significant share issuance activity in the recent financial data.

Recent events, including analyst estimates and recommendations, suggest a neutral to slightly positive outlook for AHC.AX. The mean price target of 0.53 AUD and the mean recommendation of 2.00 (indicating a "buy" rating) reflect a cautious optimism among analysts.